Vertaling van "from a one-year " (Nederlands → Frans) :

Data from a one-year Phase III trial published in “The New England Journal of Medicine” in June confirmed that Ilaris offered rapid and long-term clinical remission in CAPS patients.
Des données d’un essai de phase III sur un an publiées en juin dans «The New England Journal of Medicine» ont confirmé qu’Ilaris offrait une rémission clinique rapide et de longue durée des CAPS.

Data at AAN from TRANSFORMS, a one-year Phase III trial against interferon beta-1a (Avonex ® ), showed 80-83% of MS patients given FTY720 were relapse-free for one year compared to 69% of patients treated with Avonex ® (p< 0.001), with a safety profile for FTY720 in line with previous experience.
Lors de ce même congrès, des données provenant de TRANSFORMS, un essai de phase III d’une durée d’un an comparant FTY720 à l’interféron bêta-1a (Avonex ® ), ont montré que 80% à 83% des malades ayant reçu FTY720 n’avaient pas eu de récidive pendant un an comparé à 69% des malades traités avec Avonex ® (p< 0.001), tandis que le profil d’innocuité de FTY720 correspondait aux expériences précédentes.

Results of a one-year study, which was undertaken in response to “approvable letters” from the FDA, achieved primary efficacy and renal function targets and were also consistent with experience seen in 70 countries – including in Europe – where this medicine has been approved.
Les résultats d’une étude d’un an, entreprise en réponse à des «approvable letters» émises par la FDA, a atteints ses objectifs principaux en termes d’efficacité et de fonction rénale. Ces résultats étaient également en adéquation avec les expériences récoltées dans 70 pays – notamment en Europe – où ce médicament est autorisé.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Certican Prevention of organ 2011 III rejection – liver DEB025 Hepatitis C 2013 II - Phase III start planned in Q4 2010 Exjade Non transfusion 2011 II dependent Thalassemia HCD122 Hematological tumors ≥2014 I INC424 Myelofibrosis 2011 III - Results from a Phase I/II study published in The New England Journal of Medicine in September showed approximately 75% of myelofibrosis patients receiving INC424 twice-daily experienced rapid reduction in spleen size, which was durable for more than one year of follow-up
INC424 Myélofibrose 2011 III - Les résultats de l’étude de phase I/II publiés en septembre dans The New England Journal of Medicine montrent que 75% env. des malades atteints de myélofibrose et recevant INC424 deux fois par jour ont constaté une diminution rapide de la taille de leur rate, qui s’est maintenue au-delà d’un an de

Finally, the Board proposes the re-election of Dr. Daniel Vasella and Marjorie M.T. Yang, each for a three-year term, and Hans-Joerg Rudloff for a one-year term (as he will reach the age limit).
Enfin, le Conseil d’administration propose de réélire le D r Daniel Vasella et Marjorie M.T. Yang pour un mandat de trois ans chacun et Hans-Joerg Rudloff pour un mandat d’un an (car il sera atteint par la limite d’âge).

In just one year, about 80 000 people were diagnosed and treated in this program, and hospital admissions and deaths related to malaria have declined.
En une seule année, le projet a permis de diagnostiquer et de traiter 80’000 personnes, ce qui a aussi favorisé la diminution du nombre d’hospitalisations et de décès liés à la malaria.

45. Ro K, Gude T, Tyssen R, Aasland O. A self-referral preventive intervention for burnout among Norwegian nurses: One-year follow-up study.
44. Ro K, Gude T, Tyssen R, Aasland O. A self-referral preventive intervention for burnout among Norwegian nurses: One-year follow-up study.

44. Ro K, Gude T, Tyssen R, Aasland O. Counselling for burnout in Norwegian doctors: one year cohort study.
43. Ro K, Gude T, Tyssen R, Aasland O. Counselling for burnout in Norwegian doctors: one year cohort study.

This approval was based on data showing Xolair reduced asthma attacks in this age group by 34% at 24 weeks and 50% at one year.
Cette autorisation repose sur des résultats montrant que Xolair réduisait les accès d’asthme chez ce groupe d’âges de 34% sur 24 semaines et de 50% sur un an.